Navalign LLC’s Allogene Therapeutics ALLO Stock Holding History

Navalign LLC’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$103K	Hold	49,398	–	–	0.02%	130
2026 Q1	$121K	Hold	49,398	–	–	0.03%	125
2025 Q4	$67.7K	Sell	49,398 -10,467	-17%	-$13.8K	0.02%	176
2025 Q3	$74.2K	Hold	59,865	–	–	0.02%	120
2025 Q2	$67.6K	Hold	59,865	–	–	0.02%	114
2025 Q1	$87.4K	Hold	59,865	–	–	0.02%	113
2024 Q4	$128K	Sell	59,865 -15,500	-21%	-$38.2K	0.04%	115
2024 Q3	$211K	Hold	75,365	–	–	0.06%	114
2024 Q2	$176K	Hold	75,365	–	–	0.06%	114
2024 Q1	$337K	Hold	75,365	–	–	0.11%	101
2023 Q4	$242K	Hold	75,365	–	–	0.08%	119
2023 Q3	$239K	Hold	75,365	–	–	0.09%	127
2023 Q2	$375K	Hold	75,365	–	–	0.15%	89
2023 Q1	$372K	Hold	75,365	–	–	0.16%	91
2022 Q4	$474K	Hold	75,365	–	–	0.2%	94
2022 Q3	$814K	Hold	75,365	–	–	0.37%	50
2022 Q2	$859K	Buy	75,365 +1,094	+1%	+$9.71K	0.38%	53
2022 Q1	$623K	Buy	74,271 +9,843	+15%	+$103K	0.26%	75
2021 Q4	$961K	Hold	64,428	–	–	0.38%	54
2021 Q3	$1.66M	Hold	64,428	–	–	0.7%	25
2021 Q2	$1.68M	Buy	+64,428	New	+$1.84M	0.71%	24

Other funds holding ALLO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

RBI

Raiffeisen Bank International Vienna, Austria $8.53B AUM 46.94% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Navalign LLC's ALLO Position: Q2 2026 in Review

Navalign LLC held its Allogene Therapeutics (ALLO) position steady in Q2 2026 at 49,398 shares worth $103K. The position accounts for 0.02% of the portfolio, ranked #130.

Navalign LLC first reported a position in ALLO in Q2 2021 and has held it in 21 quarters since. The position peaked at $1.68M in Q2 2021. 71 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

Navalign LLC held 49,398 shares of Allogene Therapeutics worth $103K as of Q2 2026.
Navalign LLC left its Allogene Therapeutics share count unchanged in Q2 2026.
Allogene Therapeutics made up 0.02% of Navalign LLC's portfolio in Q2 2026, its #130 holding.
Navalign LLC first reported a position in Allogene Therapeutics in Q2 2021 and has held it in 21 quarters since.
Navalign LLC's Allogene Therapeutics position peaked at $1.68M in Q2 2021.
71 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Navalign LLC's 13F filing for Q2 2026, filed 28 Jul 2026.